WCG calls on 1200 member institutions to adopt Accelerated Clinical Trial Agreement

By Zachary Brennan contact

- Last updated on GMT

Related tags: Contract, Contract research organization

WCG calls on 1200 member institutions to adopt Accelerated Clinical Trial Agreement
As part of efforts to reduce clinical trial start-up times, WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for human research, said it will encourage the 1,200 members of its research network to accept the Accelerated Clinical Trial Agreement (ACTA) as their default agreement for industry-sponsored, multi-center trials. 

The ACTA was developed by the NIH’s National Center for Advancing Translational Sciences (NCATS) to help in negotiations between institutional research sites and sponsors. The document aims to help sponsors and sites negotiate regulatory and contractual obligations in a more straightforward and unambiguous way. 

Stuart Horowitz, WCG’s president of institutions and institutional services, told Outsourcing-Pharma.com that although it’s not perfect, after two years in the making, the ACTA has the potential to accelerate research. 

However, the way the ACTA is currently written, it won’t work when CROs (contract research organizations) are involved, Horowitz said. 

There will be a CRO version coming out in the next week or two and we will work with our CRO partners to get that finalized​,” he added. 

To date, approximately 225 institutions – half of which are WCG members -- have agreed to the terms of the ACTA. As far as how many more institutions will pick up the ACTA, Horowitz said it’s tough to predict. “This is so new that it’s just in the process of being piloted… so time will tell​.” 

Data from a 2010 CTSA [Clinical and Translational Science Awards]​ Contracts Processing Study showed that an average contract negotiation time of 55 days could be reduced to 22 days if a ‘master agreement’ was used​,” said Petra Kaufmann, director of the NCATS Division of Clinical Innovation. “That information prompted us to challenge CTSA  awardees to develop an efficient contract that, if adopted, could help reduce delays in trial start-up. We are pleased that WCG has recognized the potential of the ACTA, and delighted to have their support in disseminating its use​.”

Related news

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars